PsyAccess Launches Registry-Verified Directory of Psychedelic Treatment in 27 European Countries

PsyAccess launches a registry-verified directory of licensed ketamine- and psychedelic-assisted therapy providers across 27 European countries.



PsyAccess Homepage

LISBON, PORTUGAL, September 17, 2026 /EINPresswire.com/ -- For a class of medicine that fills headlines, licensed esketamine and ketamine treatment, recruiting clinical trials, and authorised psychedelic-assisted therapy are remarkably hard to actually reach in Europe. The information is scattered across 27 regulatory systems in a dozen languages, clinic marketing sits next to fact, and when someone asks an AI assistant where to go, there has been no reliable source for it to cite. PsyAccess, launching today, is the map: a free directory of 487 licensed and registry-traceable records across 27 countries, each with the source link printed on the listing.

> PsyAccess is the patient-facing part of how we think this field gets better: on trust, not hype."
>
> *Iurii Filatov, Co-Founder & CEO, Pink Elephant Group*

Inclusion verifies licensing and factual claims against official registers, never clinical quality, efficacy or the treatment itself. PsyAccess does not rank providers.

The first thing the map shows is how uneven access is. Of the 103 providers authorised to deliver psychedelic-assisted therapy in the strict sense, 101 are practitioners working under Switzerland's per-patient authorisation scheme, and 2 are German sites in an authorised psilocybin compassionate-use programme (BfArM, §3 BtMG). Every other country in the directory has none. Seven countries — Cyprus, Estonia, Latvia, Lithuania, Malta, Romania and Slovakia — have exactly one verified provider of any kind. "Legal" and "reachable," it turns out, are very different words depending on where a

patient happens to live.

What makes the directory unusual is not that it exists, but how it is built. In a field where clinic marketing is often indistinguishable from fact, and US-style directories list whoever pays, PsyAccess does close to the opposite. Listing is free, and no payment affects whether a provider is included, how it ranks, or how its record is verified. Every record needs at least two independent sources, the standard a newsroom applies to a fact, and wherever a public register exists, one of them has to be that register. A listing that cannot clear the bar is not quietly labelled “unverified.” It is removed, and stays removed until it can be proven again.

The routes are not interchangeable, and the directory keeps them apart: 212 licensed esketamine centres, 129 clinical trial sites, 103 authorised psychedelic-assisted therapy providers, and 43 ketamine or ketamine-assisted psychotherapy clinics. Of the 129 trial sites, participation is research under a study protocol, not a form of available clinical care. Counting only routes a patient can actually be treated through, the map holds 358 providers, not 487.

“PsyAccess is the patient-facing part of how we think this field gets better: on trust, not hype. Every record traces to an official register, and anything we can't prove, we delete rather than dress up. PsyAccess is part of Pink Elephant Group, and it earns that trust by running independently of everything else we do.”
Iurii Filatov Co-Founder & CEO, Pink Elephant Group

“As interest in psychedelic medicine grows, patients face an increasingly complex landscape spanning authorised treatments, off-label clinical practice and investigational therapies available only through research. Simply finding a provider online tells you very little about the regulatory status, evidence base or safeguards surrounding that care. Transparent, source-linked infrastructure that helps people understand what is genuinely available, and that clearly distinguishes clinical treatment from research participation, is an important step towards safer, better informed and more equitable access.”
Dr Rayyan Zafar PhD, MRSB, Neuropsychopharmacologist and UKRI Postdoctoral Fellow

“When someone is suffering and cannot find a clear path, it is very easy to end up turning to improvised options out of sheer desperation. Mental health care requires a baseline: a coordinated team, a clear ethical framework, and a safe environment. This is not about judging anyone. It is about recognising that supporting vulnerable people demands structure and collective expertise.”
Òscar Parés Founder and CEO, Clínica Synaptica

“The past decade has seen a surge of demand for psychedelic therapies, but patients often don't know where to turn for treatments with robust clinical oversight. PsyAccess is helping to close that gap. With nearly 490 verified providers listed across Europe, this is a valuable resource for identifying licensed clinics and research centres. I expect the number of treatment centres will proliferate in the coming years as psychedelics reach approval, so a free and up-to-date directory

will only increase in utility."
Tom McDonald Board member and co-founder, Clerkenwell Health

"As a doctor administering ketamine treatments, patient safety and strict clinical protocols are my highest priorities. Too many patients seeking psychedelic therapy in Europe end up in unregulated or unverified settings simply because they don't know where else to look. A platform like psyaccess.health is a much-needed medical filter, connecting patients with rigorous, professionally supervised care."
Dr Christopher Gauci MD MRCS(Ed) EDAIC, Anaesthetist and intensive care specialist

PsyAccess is also unusually direct about what it is not. It does not rank providers or name "best" clinics. It makes no claim about whether treatment works. Coverage is thinner in some countries because access genuinely is, and where a country has two licensed sites, the directory shows two. All of this is stated on the site itself, not buried in a disclaimer.

The directory is free, available in five languages (English, German, Spanish, French and Polish), and stores nothing from its in-browser eligibility check unless a user chooses to send an enquiry. The full dataset is published openly under CC BY at psyaccess.health/data. Any provider can correct or remove its own listing at psyaccess.health/for-providers. It is live now at psyaccess.health, and the full verification methodology is public at psyaccess.health/methodology.

About PsyAccess
PsyAccess is a free, registry-verified directory of licensed esketamine and ketamine treatment, clinical trial sites and authorised psychedelic-assisted therapy across 27 European countries. Every listing traces to an official source, carries a last-verified date, and is re-checked on a fixed 90-day cycle. Inclusion verifies licensing and factual claims against official registers, never clinical quality, efficacy or the treatment itself. Providers pay nothing to be listed and no payment affects inclusion, ranking or verification. PsyAccess is part of Pink Elephant Group and operates independently within it.
psyaccess.health

Anna Maximova
Pink Elephant Group
a.maximova@pink-elephant.co
Visit us on social media:
LinkedIn
X
Other

This press release can be viewed online at: https://www.einpresswire.com/article/943063738

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.